10-Q 1 f10q0322_allaritythera.htm QUARTERLY REPORT

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarterly Period Ended March 31, 2022

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number: 001-41160

 

ALLARITY THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware   87-2147982
(State or Other Jurisdiction Of
Incorporation or Organization)
  (I.R.S. Employer
Identification Number)

 

210 Broadway, Suite 201, Cambridge, MA   02139
(Address of Principal Executive Offices)   (Zip Code)

 

(401) 426-4664

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report) 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   ALLR   The Nasdaq Stock Market LLC

  

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒  No ☐

 

Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
Emerging growth company     

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

As of May 27, 2022, the registrant had 9,283,295 shares of common stock outstanding.

 

 

 

 

 

 

Table of Contents

 

    Page
  Forward Looking Statements ii
     
PART I – FINANCIAL INFORMATION  
   
Item 1. Condensed Consolidated Financial Statements 1
  Condensed Consolidated Balance Sheets as at March 31, 2022 (Unaudited) and December 31, 2021 1
  Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2022 and March 31, 2021 (Unaudited) 2
  Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity for the three months ended March 31, 2022 and March 31, 2021 (Unaudited) 3
  Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and March 31, 2021 (Unaudited) 4
  Notes to Condensed Consolidated Financial Statements for the three months ended March 31, 2022 and March 30, 2021 (Unaudited) 5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 26
Item 3. Quantitative and Qualitative Disclosures About Market Risk 32
Item 4. Controls and Procedures 32
     
PART II – OTHER INFORMATION  
   
Item 1. Legal Proceedings 34
Item 1A. Risk Factors 34
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 34
Item 3. Defaults Upon Senior Securities 34
Item 4. Mine Safety Disclosures 34
Item 5. Other Information 34
Item 6.  Exhibits 35
   
  Signatures 36

 

i 

 

 

Unless the context indicates otherwise, references in this Quarterly Report on Form 10-Q to the “Company,” “Allarity,” “we,” “us,” “our” and similar terms refer to Allarity Therapeutics, Inc., Allarity Therapeutics A/S (as predecessor) and its respective consolidated subsidiaries.

 

FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements in this report other than statements of historical fact are forward-looking statements for purposes of these provisions, including any statements of the Company’s plans and objectives for future operations, the Company’s future financial or economic performance (including known or anticipated trends), and the assumptions underlying or related to the foregoing. Statements that include the use of terminology such as “may,” “will,” “expects,” “plans,” “anticipates,” “estimates,” “potential,” or “continue,” or the negative thereof, or other comparable terminology, are forward-looking statements. These risks and uncertainties include, but are not limited to, the factors described in the section captioned “Risk Factors” in our Annual Report on Form 10-K (“Form 10-K”), filed with the Securities and Exchange Commission (“SEC”) on May 17, 2022. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. You should read these factors and the other cautionary statements made in this report as being applicable to all related forward-looking statements wherever they appear in this report. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

 

Any forward-looking statements contained in this Quarterly Report are only estimates or predictions of future events based on information currently available to our management and management’s current beliefs about the potential outcome of future events. Whether these future events will occur as management anticipates, whether we will achieve our business objectives, and whether our revenues, operating results or financial condition will improve in future periods are subject to numerous risks. There are a number of important factors that could cause actual results to differ materially from the results anticipated by these forward-looking statements. These important factors include those that we discuss under the heading “Risk Factors” in this Quarterly Report and in other reports filed from time to time with the SEC. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

 

All forward-looking statements and descriptions of risks included in this report are made as of the date hereof based on information available to the Company as of the date hereof, and except as required by applicable law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. You should, however, consult the risks and other disclosures described in the reports the Company files from time to time with the SEC after the date of this report for updated information.

 

ii 

 

 

PART I – FINANCIAL INFORMATION

 

Item 1. Condensed Consolidated Financial Statements

 

ALLARITY THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

(U.S. dollars in thousands, except for share and per share data)

 

 

   March 31,
2022
$
   December 31,
2021
$
 
   (Unaudited)     
ASSETS        
Current assets:        
Cash   14,544    19,555 
Other current assets   147    625 
Prepaid expenses   1,249    36 
Tax credit receivable   1,271    838 
Total current assets   17,211    21,054 
Non-current assets:          
Investment in Lantern Pharma Inc. stock   314    350 
Property, plant and equipment, net   6    8 
Operating lease right of use assets   65    86 
Intangible assets, net   13,694    28,135 
Total assets   31,290    49,633 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable   5,799    698 
Accrued liabilities   1,342    8,590 
Income taxes payable   52    60 
Operating lease liabilities, current   82    98 
Derivative liabilities   3,171    
 
Warrant liability   2,265    11,273 
Total current liabilities   12,711    20,719 
Non-current liabilities          
Convertible promissory note and accrued interest, net   1,005    979 
Operating lease liabilities, net of current portion   
    9 
Deferred tax   700    1,961 
Derivative liabilities   
    7,181 
Total liabilities   14,416    30,849 
Commitments and contingencies (Note 20)   
 
    
 
 
Redeemable convertible preferred stock          
Series A Convertible Preferred stock $0.0001 par value (500,000 shares authorized) 17,827 and 19,800 issued and outstanding at March 31, 2022 and December 31, 2021 respectively   2,142    632 
Stockholders’ equity          
Common stock, $.0001 par value (30,000,000 shares authorized) shares issued and outstanding at March 31, 2022 and December 31, 2021 were 8,842,290 and 8,096,014 respectively   885    810 
Additional paid-in capital   84,233    84,434 
Accumulated other comprehensive (loss)   (814)   (600)
Accumulated deficit   (69,572)   (66,492)
Total stockholders’ equity   14,732    18,152 
Total liabilities, redeemable convertible preferred stock & stockholders’ equity   31,290    49,633 

 

See accompanying notes to condensed consolidated financial statements.

 

1

 

 

ALLARITY THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
(U.S. dollars in thousands, except for share and per share data)

 

   Three months ended
March 31,
 
   2022$   2021$ 
Operating expenses:        
Research and development   1,289    1,251 
Impairment of intangible assets   14,007    
 
General and administrative   3,013    1,211 
Total operating expenses   18,309    2,462 
Loss from operations   (18,309)   (2,462)
Other income (expenses)          
Gain on the sale of IP   1,780    
 
Interest expense   (39)   (79)
Finance expense   
    (87)
Loss on investment   (36)   (113)
Foreign exchange losses   (269)   (39)
Change in fair value adjustment of derivative and warrant liabilities   12,566    45 
Loss on extinguishment of convertible debt   
    (116)
Change in fair value of convertible debt   
    (201)
Net other income (loss)   14,002    (590)
Net loss for the period before tax benefit (expense)   (4,307)   (3,052)
Income tax benefit (expense)   1,227    (33)
Net loss   (3,080)   (3,085)
Deemed dividend of 8% on Preferred stock   (1,572)   
 
Net Loss Attributable to common stockholders   (4,652)   (3,085)
Basic and diluted net loss per common stock   (0.56)   (0.68)
Weighted-average number of common stock outstanding, basic and diluted   8,288,371    4,533,430 
Other comprehensive loss, net of tax:          
Net loss   (3,080)   (3,085)
Change in cumulative translation adjustment   (214)   (459)
Change in fair value attributable to instrument specific credit risk   
    (6)
Comprehensive loss attributable to common stockholders   (3,294)   (3,550)

 

See accompanying notes to condensed consolidated financial statements.

 

2

 

 

ALLARITY THERAPEUTICS, INC.
 

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK
AND STOCKHOLDERS’ EQUITY
For the Three months ended March 31, 2022 and 2021
(Unaudited)

(U.S. dollars in thousands, except for share data) 

 

   Series A Convertible
Preferred Stock
   Common Stock  

Additional

Paid in

   Accumulated
Other
Comprehensive
   (Accumulated   Total
Stockholders’
 
   Number  

Value, net

$

   Number   Value
$
   Capital
$
   (Loss) Income
$
   Deficit)
$
   Equity
$
 
Balance, December 31, 2020       
    4,252,021    426    62,482    1,375    (39,844)   24,439 
Debt conversion        
 
    528,810    53    2,331    
    
    2,384 
Stock based compensation       
        
    195    
    
    195 
Currency translation adjustment       
        
    
    (459)   
    (459)
Fair value of instrument specific Credit risk       
        
    
    (6)   
    (6)
Loss for the period       
        
    
    
    (3,085)   (3,085)
Balance, March 31, 2021        
 
    4,780,831    479    65,008    910    (42,929)   23,468 

  

    Series A Convertible
Preferred Stock
    Common Stock    

Additional

Paid in

    Accumulated
Other
Comprehensive
    (Accumulated     Total
Stockholders’
 
    Number    

Value, net

$

    Number     Value
$
    Capital
$
    (Loss) Income
$
    Deficit)
$
    Equity
$
 
Balance, December 31, 2021     19,800       632       8,096,014       810       84,434       (600 )     (66,492 )     18,152  
Conversion of preferred stock into common stock, net     (1,973 )     (62 )     746,276       75       306                   381  
Deemed dividend of 8% on preferred stock           1,572                   (1,572 )                 (1,572 )
Stock based compensation                             1,065                   1,065  
Currency translation adjustment                                   (214 )           (214 )
Loss for the period                                         (3,080 )     (3,080 )
Balance, March 31, 2022     17,827       2,142       8,842,290       885       84,233       (814 )     (69,572 )     14,732  

 

See accompanying notes to condensed consolidated financial statements.

 

3

 

 

ALLARITY THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(U.S. dollars in thousands)

 

   Three months ended
March 31,
 
   2022$   2021$ 
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net loss for the period   (3,080)   (3,085)
Adjustments to reconcile net loss to net cash used in operating activities:          
Gain on the sale of IP   (1,780)   
 
Depreciation and amortization   23    56 
Intangible asset impairment   14,007    
 
Stock-based compensation   1,065    195 
Unrealized foreign exchange loss   255    39 
Non-cash finance expense   
    87 
Non-cash interest   26    24 
Loss on investment   36    113 
Change in fair value adjustment of convertible debt   
    201 
Loss on extinguishment of convertible debt   
    116 
Change in fair value adjustment of warrant and derivative liabilities   (12,566)   (45)
Deferred income taxes   (1,227)   33 
Changes in operating assets and liabilities:          
Other current assets   470    (95)
Tax credit receivable   (455)   (403)
Prepaid expenses   (1,227)   155 
Accounts payable   5,036    108 
Accrued liabilities   (6,308)   (32)
Income taxes payable   (7)    
Operating lease liability   (23)   (34)
Net cash used in operating activities   (5,755)   (2,567)
CASH FLOWS FROM INVESTING ACTIVITIES:          
Proceeds from the sale of IP   809    
 
Net cash provided by investing activities   809    
 
CASH FLOWS FROM FINANCING ACTIVITIES:          
Line of credit   
    35 
Proceeds from convertible loan   
    1,140 
Loan proceeds   
    1,150 
Net cash provided by financing activities   
    2,325 
Net decrease in cash   (4,946)   (242)
Effect of exchange rate changes on cash   (65)   49 
Cash, beginning of period   19,555    298 
Cash, end of period   14,544    105 
Supplemental information          
Cash paid for income taxes   1    
 
Cash paid for interest   13    55 
Supplemental disclosure of non-cash investing and financing activities:          
Offset of payable against receivable from sale of IP   971    
 
Conversion of Series A Convertible Preferred stock to equity, net   381    
 
Accrued liability on Series A Preferred shares   134    
 
Deemed 8% dividend on Series A Preferred shares   1,572    
 
Conversion of convertible debt to equity   
    2,329 
Shares issued to settle accounts payable   
    55 
Right of use asset modification   
    145 

 

See accompanying notes to condensed consolidated financial statements.

 

4

 

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended March 31, 2022 and March 31, 2021

(UNAUDITED)

(U.S. dollars in thousands, except for share and per share data and where otherwise noted)

 

1. Organization, Principal Activities, and Basis of Presentation

 

Allarity Therapeutics, Inc. and Subsidiaries (the “Company”) is a clinical stage pharmaceutical company that develops drugs for the personalized treatment of cancer using drug specific companion diagnostics (cDx) generated by its proprietary drug response predictor technology, DRP®. Additionally, the Company, through its Danish subsidiary, Allarity Denmark (previously Oncology Venture ApS), specializes in the research and development of anti-cancer drugs.

 

The Company’s principal operations are located at Venlighedsvej 1, 2970 Horsholm, Denmark. The Company’s United States operations are located at 210 Broadway #201, Cambridge, MA 012139, United States of America.

  

(a) Liquidity and Going Concern

 

The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The accompanying financial statements do not reflect any adjustments relating to the recoverability and reclassifications of assets and liabilities that might be necessary if the Company is unable to continue as a going concern.

  

Pursuant to the requirements of Accounting Standard Codification (ASC) 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date of these financial statements, and (1) is probable that the plan will be effectively implemented within one year after the date the financial statements are issued, and (2) it is probable that the plan, when implemented, will mitigate the relevant condition or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date the financials are issued. Certain elements of the Company’s operating plan to alleviate the conditions that raise substantial doubt are outside of the Company’s control and cannot be included in management’s evaluation under the requirements of Accounting Standard Codification (ASC) 205-40.

 

Since inception, the Company has devoted substantially all its efforts to business planning, research and development, clinical expenses, recruiting management and technical staff, and securing funding via collaborations. The Company has historically funded its operations with proceeds received from its collaboration arrangements, sale of equity capital and proceeds from sales of convertible notes.

 

The Company has incurred significant losses and has an accumulated deficit of $69.6 million as of March 31, 2022. As of May 27, 2022, our cash is insufficient to fund our current operating plan and planned capital expenditures for the next 12 months. These conditions give rise to a substantial doubt over the Company’s ability to continue as a going concern.

 

Management’s plans to mitigate the conditions or events that raise substantial doubt include additional funding through public equity, private equity, debt financing, collaboration partnerships, or other sources. There are no assurances, however, that the Company will be successful in raising additional working capital, or if it is able to raise additional working capital, it may be unable to do so on commercially favorable terms. The Company’s failure to raise capital or enter into other such arrangements if and when needed would have a negative impact on its business, results of operations and financial condition and its ability to develop its product candidates.

 

5

 

 

Although management continues to pursue its funding plans, there is no assurance that the Company will be successful in obtaining sufficient funding to fund continuing operations on terms acceptable to the Company, if at all. Accordingly, based upon cash on hand at the issuance date of these financial statements the Company does not have sufficient funds to finance its operations for at least twelve months from the issuance date and therefore has concluded that substantial doubt exists about the Company’s ability to continue as a going concern.

 

(b) Basis of Presentation

 

The accompanying unaudited condensed interim consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP” or “GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”).

 

The accompanying unaudited condensed interim consolidated financial statements contain all normal and recurring adjustments necessary to state fairly the consolidated balance sheet, results of operations and comprehensive loss, statements of changes in redeemable convertible preferred stock and stockholders’ equity, and cash flows of the Company for the interim periods presented. Except as otherwise disclosed, all such adjustments consist only of those of a normal recurring nature. Operating results for the three months ended March 31, 2022, are not necessarily indicative of the results that may be expected for the current year ending December 31, 2022. The financial data presented herein should be read in conjunction with the audited consolidated financial statements and accompanying notes as of and for the years ended December 31, 2021, and 2020 thereto included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on May 17, 2022.

 

The preparation of these unaudited condensed interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. The results of operations and cash flows for the interim periods included in these condensed consolidated financial statements are not necessarily indicative of the results to be expected for any future period or the entire fiscal year.

 

These condensed consolidated financial statements and notes do not include all disclosures required by U.S. GAAP and should be read in conjunction with the Company’s audited consolidated financial statements as of and for the year ended December 31, 2021, and the notes.

 

(c) Principles of Consolidation

 

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries:

 

Name   Country of Incorporation
Allarity Acquisition Subsidiary Inc.   United States
Allarity Therapeutics Europe ApS (formerly Oncology Venture Product Development ApS)   Denmark
Allarity Therapeutics Denmark ApS (formerly OV-SPV2 ApS)   Denmark
MPI Inc.   United States
Oncology Venture US Inc.   United States

 

All intercompany transactions and balances, including unrealized profits from intercompany sales, have been eliminated upon consolidation.

 

6

 

 

(d) Risks and Uncertainties

 

The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel and collaboration partners, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations, and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval prior to commercialization. Even if the Company’s research and development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.

 

The extent of the impact and effects of the coronavirus (COVID-19) on the operation and financial performance of the Company’s business will depend on future developments, including the duration and spread of the outbreak and varying virus mutations, related travel advisories and restrictions, the recovery time of disrupted research services, the consequential staff shortages, and research and development delays, or the uncertainty with respect to the accessibility of additional liquidity or capital markets, all of which are highly uncertain and cannot be predicted. If the Company’s operations are impacted by the outbreak for an extended period, the Company’s results of operations or liquidity may be materially adversely affected. 

 

(e) Impact of the Russia-Ukraine War

 

There have been immense flows of refugees to Europe and Denmark is ready to facilitate and to accept refugees from the Ukraine. It is far too early to estimate how many migrants Denmark will facilitate, but immigration officials have begun preparing to accept Ukrainian refugees. Being a North Atlantic Treaty Organization (NATO) member, Denmark will strengthen its own national preparedness as well as that of the NATO defense alliance. The Ukraine crisis has not yet had an impact on our results of operations however we expect it may have an impact on the costs of materials we purchase for our laboratory operations in Denmark but, we cannot predict the impact now.

 

2. Summary of Significant Accounting Policies

 

(a) Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting years. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the fair value of the Series A preferred shares, warrants, convertible debt, and the accrual for research and development expenses, fair values of acquired intangible assets and impairment review of those assets, share based compensation expense, and income tax uncertainties and valuation allowances. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed considering reasonable changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known and if material, their effects are disclosed in the notes to the condensed consolidated financial statements. Actual results could differ from those estimates or assumptions.

 

(b) Foreign currency and currency translation

 

The functional currency is the currency of the primary economic environment in which an entity’s operations are conducted. The Company and its subsidiaries operate mainly in Denmark and the United States. The functional currencies of the Company’s subsidiaries are their local currency.

 

The Company’s reporting currency is the U.S. dollar. The Company translates the assets and liabilities of its Denmark subsidiaries into the U.S. dollar at the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during each monthly period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the condensed consolidated statements of changes in redeemable convertible preferred stock and stockholders’ equity as a component of accumulated other comprehensive (loss).

 


7

 

 

Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured into the functional currency at rates of exchange prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are re-measured into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net loss for the respective periods. Adjustments that arise from exchange rate translations are included in other comprehensive income (loss) in the consolidated statements of operations and comprehensive loss as incurred

 

(c) Concentrations of credit risk and of significant suppliers

 

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash. The Company maintains its cash in financial institutions in amounts that could exceed government-insured limits. The Company does not believe it is subject to additional credit risks beyond those normally associated with commercial banking relationships. The Company has not experienced losses on its cash accounts and management believes, based upon the quality of the financial institutions, that the credit risk regarding these deposits is not significant. The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply its requirements for supplies and raw materials related to these programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.

 

(d) Cash

 

Cash consists primarily of highly liquid investments with original maturities of three months or less at date of purchase to be cash equivalents. The Company had no cash equivalents or restricted cash on March 31, 2022, and December 31, 2021.

 

(e) Impairment of long-lived assets

 

Long-lived assets consist of property, plant and equipment, and intangible assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. An impairment loss would be recognized as a loss from operations when estimated undiscounted future cash flows expected to result from the use of an asset group or the estimated return on investment are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flow or return on investment calculations.

 

(f) Accumulated other comprehensive (loss)

 

Accumulated other comprehensive loss includes net loss as well as other changes in stockholders’ equity (deficit) that result from transactions and economic events other than those with shareholders. The Company records unrealized gains and losses related to foreign currency translation and instrument specific credit risk as components of other accumulated comprehensive loss in the Condensed Consolidated Statements of Operations and Comprehensive Loss. During the three months ended March 31, 2022, and March 31, 2021, the Company recorded accumulated foreign currency translation losses of ($214) and ($459) respectively; and instrument specific credit risk losses of $0 and ($6) respectively.

 

8

 

 

(g) Contingencies

 

Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. At each reporting date, the Company evaluates whether a potential loss amount or a potential loss range is probable and reasonably estimable under the provisions of the authoritative guidelines that address accounting for contingencies. The Company expenses costs as incurred in relation to such legal proceedings as general and administrative expense within the condensed consolidated statements of operations and comprehensive loss.

 

(h) JOBS Act accounting election

 

The Company is an “emerging growth company”, as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies; however, the Company may adopt new or revised accounting standards early if the standard allows for early adoption.

 

(i) Recently adopted accounting pronouncements

 

In May 2021, the FASB issued ASU No. 2021-04 — Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options — to clarify the accounting by issuers for modifications or exchanges of equity-classified written call options. The framework applies to freestanding written call options, such as warrants, that were and remain equity classified by the issuer after the modification and are not in the scope of another Codification Topic. The framework applies regardless of whether the modification is through an amendment to the existing terms or issuance of a replacement warrant. The effect of the modification of the warrant is measured as the difference in its fair value immediately before and after the modification. The effect is recognized in the same manner as if cash had been paid as consideration. Additionally, other modifications may need to be accounted for as a cost to the issuing entity based on the substance of the transaction. The Company is required to apply the amendments within this ASU prospectively to modifications or exchanges occurring on or after the effective date of the amendment. The Company adopted this ASU on January 1, 2022, with no significant impact on its condensed consolidated financial statements and related disclosures.

 

9

 

 

In November 2021, the FASB issued ASU 2021-10 — Government Assistance — Disclosures by Business Entities about Government Assistance — to require disclosures about transactions with a government that have been accounted for by analogizing to a grant or contribution accounting model to increase transparency about (1) the types of transactions, (2) the accounting for the transactions, and (3) the effect of the transactions on an entity’s financial statements. The ASU is effective prospectively or retrospectively for annual periods beginning after December 15, 2021, with early adoption permitted. The Company adopted this ASU on January 1, 2022, with no significant impact on its condensed consolidated financial statements and related disclosures.

 

(j) Recently Issued Accounting Pronouncements

 

Changes to GAAP are established by the Financial Accounting Standards Board (the “FASB”) in the form of accounting standards updates (“ASUs”) to the FASB’s Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. All other ASUs issued through the date of these financial statements were assessed and determined not to be applicable or are expected to have minimal impact on the Company’s condensed consolidated financial position and results of operations.

 

3. Other Current Assets

 

The Company’s other current assets are comprised of the following:

 

   March 31,
2022
$
   December 31,
2021
$
 
Deposits   57    53 
Salary deposit   64    65 
Value added tax (“VAT”) receivable   26    507 
Net other current assets   147    625 

 

4. Prepaid Expenses

 

   March 31,
2022
$
   December 31,
2021
$
 
Prepaid insurance   1,227    14 
Other prepayments   22    22 
    1,249    36 

 

10

 

 

5. Investment

 

The Company owns 43,898 common shares in Lantern Pharma Inc. because of a prior license agreement made with Lantern Pharma in 2017. During June 2020 Lantern Pharma became publicly listed. As at March 31, 2022 the fair value of the shares was $314. In the three months ended March 31, 2022, and March 31, 2021 the Company recognized a loss on its shares in Lantern Pharma of $36 and $113 respectively.

 

   March 31,   December 31, 
   2022
$
   2021
$
 
Opening balance   350    845 
Loss recognition   (36)   (495)
Ending balance   314    350 

 

6. Property, plant and equipment, net

 

Property, plant and equipment, net consisted of the following (in thousands):

 

   March 31,
2022
   December 31,
2021
 
Laboratory equipment   329    336 
Less: accumulated depreciation   (323)   (328)
    6    8 

 

Depreciation expense for property, plant and equipment and right of use assets for the three months ended March 31, 2022, and March 31, 2021 was $23 and $56 respectively.

 

7. Intangible assets

 

Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:

 

   As of March 31, 2022 
   Cost   Accumulated
Impairment
   Accumulated
Amortization
   Net 
IPR&D Assets  $35,151   $(21,457)   
   $13,694 
Acquired patents   78    
    (78)   
 
Total intangible assets  $35,229   $(21,457)   (78)  $13,694 

 

   As of December 31, 2021 
   Cost   Accumulated
Impairment
   Accumulated
Amortization
   Net 
IPR&D Assets  $35,896   $(7,761)      $28,135 
Acquired patents   78        (78)    
Total intangible assets  $35,974   $(7,761)   (78)  $28,135 

 

11

 

 

As a result of both the Company’s February 15, 2022, receipt of a Refusal to File (“RTF”) from the U.S. Food and Drug Administration regarding the Company’s new drug application (“NDA”) for Dovitinib, and the current depressed state of the Company’s stock price, the Company has performed an impairment assessment on its individual intangible assets utilizing a discounted cash flow model with a weighted average cost of capital (“WACC”) of 16%, and recognized an impairment charge of $14,007 during the three month period ended March 31, 2022. Individually material development projects in progress are as follows:

 

   March 31,   December 31, 
   2022
$
   2021
$
 
Stenoparib   13,694    25,407 
Dovitinib       2,728 
Total   13,694    28,135 

 

8. Accrued liabilities

 

The Company’s accrued liabilities are comprised of the following: 

 

   March 31,   December 31, 
   2022
$
   2021
$
 
Development cost liability   359    6,750 
Payroll accruals   290    1,088 
Accrued Board member fees   68    54 
Accrued audit and legal   298    316 
Accrued liability on Series A Preferred Stock   134    
 
Other   193    382 
    1,342    8,590 

 

9. Loan

 

2021 Loan

 

Effective March 22, 2021, the Company received a loan facility of up to $2,900 (SEK 25 million), net of a 3% loan origination fee of $87 (SEK 750 thousand), recorded as finance costs in the condensed consolidated statement of operations and comprehensive loss; bearing interest at 3% per month, and due on June 23, 2021. During the three month period ended March 31, 2021 the Company received $1,150 pursuant to the terms of the loan.

 

In exchange for the loan, the Company committed to complete a rights offering and issue common shares. The rights offering was completed before June 23, 2021, and as of June 23, 2021, the loan balance of $2,934 and interest of $204 were paid to the lender.

 

10. Convertible promissory note, net

 

On April 12, 2022, Allarity Therapeutics Denmark ApS (“Allarity Denmark,” or “OV-SPV2”), a subsidiary of Allarity Therapeutics Europe ApS (“Allarity Europe”), which is a wholly-owned subsidiary of Allarity Therapeutics, Inc., re-issued a Convertible Promissory Note (the “Promissory Note”) to Novartis Pharma AG, a company organized under the laws of Switzerland (“Novartis,” and together with Allarity Europe, the “License Parties”) in the principal amount of $1,000. The Promissory Note was re-issued pursuant to the First Amendment to License Agreement, with an effective date of March 30, 2022 (the “First Amendment”), entered into by and between the License Parties, which amended the License Agreement dated April 6, 2018 (the “Original Agreement”) previously entered into by the License Parties relating to the Compound (as defined in the Original Agreement). The First Amendment amends and restates Section 11.7 of the Original Agreement to add the revised Note to the list of enforceable claims in the second paragraph of Section 11.7 making the revised Note enforceable under New York law as a legal obligation of Allarity Denmark (f/k/a OV-SPV2 ApS). All other provisions of the Original Agreement and Promissory Note were unchanged and remain in full force and effect.

 

12

 

 

Prior to the 2018 Merger, on April 6, 2018 (“Effective Date”), Allarity Europe and Novartis entered a license agreement whereby Novartis granted to Allarity Europe (a) an exclusive, royalty-bearing, sublicensable, assignable license under the Licensed Data (as defined in the License Agreement) and Product-Specific Patents (as defined in the License Agreement) and (b) a non-exclusive, royalty-bearing, sublicensable, assignable license under the Platform Patents (as defined in the License Agreement), in the case of (a) and (b) solely to develop and otherwise commercialize the Licensed Product (as defined in the License Agreement) in any and all field related to therapeutic and/or diagnostic uses related to cancer in humans worldwide and to manufacture the compound TKI258 (a.k.a. Dovitinib) for use in a Licensed Product as of the Effective Date.

 

In consideration of the licenses and rights granted, Allarity Europe paid Novartis a one-time, non-refundable, non-creditable upfront payment consisting of $1,000 (“Upfront Payment”) and issued to Novartis a Promissory Note with an initial principal balance equal to $1,000, which Allarity Europe caused its affiliate, OV-SPV2, to issue to Novartis. In accordance with the terms of the Promissory Note, all payments shall be applied first to accrued interest, and thereafter to principal. The outstanding principal amount of the Note, plus any accrued interest thereon, shall be due and payable on the earlier to occur of: (i) the seventh (7th) anniversary of April 6, 2018; and (ii) an event of default (the “Maturity Date”).

 

The Promissory Note pays simple interest on the outstanding principal amount from the date until payment in full, which interest shall be payable at the rate of five percent (5%) per annum. Interest shall be calculated on the basis of a 360-day year for the actual number of days elapsed. The entire outstanding principal balance of the Promissory Note and all accrued interest shall be fully due and payable on the Maturity Date. The Promissory Note is convertible upon an initial public offering (“IPO”) of OV-SPV2 and allows Novartis a one-time right to exchange the Convertible Promissory Note for such number of equity securities of OV-SPV2 equal to three percent (3%) of OV-SPV2’ outstanding equity securities, calculated on a fully diluted as-converted to common stock basis, held by all holders of equity securities of OV-SPV2 immediately prior to the closing of the IPO.

 

As the Promissory Note was assumed in connection with the 2018 Merger, the Company recognized the Promissory Note and related accrued interest at its fair value. The Company utilized a third-party valuation specialist to estimate the fair value of the Promissory Note and related accrued interest. Based on the specialist’s valuation, the Company recognized the Promissory Note and related accrued interest at its estimated fair value, based upon an equivalent market interest rate of 12.875%, of approximately $787 on December 31, 2019, and recognized interest expense of $93 and $99 in the years ended December 31, 2020 and December 31, 2021 respectively and a corresponding increase in liability, resulting in a net liability of $979 and $880 at each of December 31, 2021 and December 31, 2020 respectively. The Company will measure the Note at amortized cost in subsequent reporting periods.

 

The Company evaluated the Promissory Note under ASC 480 and ASC 815 and the identified embedded features inclusive of: (1) conversion upon an IPO; (2) mandatory redemption upon a change of control; and (3) mandatory redemption in the event of default; to determine if bifurcation is required pursuant to ASC 815-15-25-1. The Promissory Note is a freestanding instrument that is convertible into shares of the OV-SPV2 ApS’ common (or preferred, as the case may be) equity. The Promissory Note was not issued in conjunction with any other instrument meaning that the Promissory Note meets the definition of a freestanding instrument. Since the conversion feature meets the definition of a derivative it was evaluated for bifurcation and management determined the conversion feature requires bifurcation but because the value is not material the conversion feature has not been bifurcated at this time. The Company will continue to monitor for changes in specific facts and circumstances which may impact the conclusions reached herein.

 

13

 

 

During the three-month periods ended March 31, 2022, and March 31, 2021, the Company recorded $26 and $24 respectively to interest expense and increased the convertible promissory note liability by the same amount. The roll forward of the Promissory Notes as of March 31, 2022, and December 31, 2021, is as follows: 

 

   March 31,
2022
$
   December 31,
2021
$
 
Convertible promissory note   1,000    1,000 
Less debt discount, opening   (215)   (263)
Plus, accretion of debt discount, interest expense   13    48 
Convertible promissory note, net of discount   798    785 
Interest accretion, opening   194    143 
Interest accretion, expense   13    51 
Ending balance   1,005    979 

 

11. Convertible debt

 

On March 31, 2020 the Company entered into an agreement to issue up to $10,100 (SEK 100,000) (the “Commitment”) to be funded in tranches (“Tranches”) of ten non-interest-bearing notes (“Notes”) convertible into new shares of the Company, each with a value of $1,010 (SEK 10,000); 95% of each Tranche is received in cash, net of a 5% fee, and the conversion price of the Notes is 95% of the lowest closing volume weighted average price as reported by Bloomberg (“VWAP”). The Company accounted for the Notes issued under the FVO election whereby the financial instrument is initially measured at its issue-date estimated fair value and subsequently re-measured at estimated fair value on a recurring basis at each reporting date. The estimated fair value adjustment is presented as a single line item within other income (expense) in the accompanying condensed consolidated statements of operations under the caption “change in fair value of convertible debt”.

 

The Company determined the fair value of the Notes using a discounted cash flow valuation technique with a WACC of 15%. The Company estimates the change in fair value attributable to the instrument specific credit risk of the Notes at 1% under the fair value option and accordingly has recognized a loss of $6 in other comprehensive income during the three-month period ended March 31, 2021.

 

The roll forward of the Notes as of March 31, 2021, is as follows:

 

   March 31,
2021
$
 
Opening fair value   1,327 
Convertible debt issued in the period   1,140 
Change in fair value (loss) reported in statement operations   201 
Foreign exchange   59 
Conversion of notes to common stock   (2,329)
Ending fair value balance at March 31, 2021   398 

 

An effective interest rate determines the fair value of the Notes. The notes are unlisted and therefore, they are categorized as Level 3 in accordance with ASC 820, “Fair Value Measurements and Disclosures.” The notes were fully converted to shares during the period ended June 30, 2021.

 

14

 

 

12. Series A Preferred Stock and Common Stock Purchase Warrants

 

(a) Series A Preferred Stock Terms

 

On May 20, 2021, we entered into a Securities Purchase Agreement (the “SPA”) with 3i, LP, a Delaware limited partnership (“3i”) for the purchase and sale of 20,000 shares of our Series A Convertible Preferred Stock (the “Preferred Shares”) for $1,000 per share for an aggregate purchase price of $20 million (the “PIPE Investment”) with accompanying common stock purchase warrants (the “3i Warrants”). On December 8, 2021, the Board adopted resolutions to create a series of twenty thousand (20,000) shares of preferred stock, par value $0.0001, designated as “Series A Convertible Preferred Stock.” On December 14, 2021, we filed a Certificate of Designations (the “COD”) setting forth the rights, preferences, privileges and restrictions for 20,000 shares of Series A Convertible Preferred Stock (the “Series A Preferred Stock”). On December 20, 2021, we issued 20,000 shares of Preferred Stock at $1,000 per share and a common stock purchase warrant to purchase 2,018,958 shares of common stock at an initial exercise price of $9.9061 to 3i, LP for an aggregate purchase price of $20 million.

 

Except to the extent that the holders of at least a majority of the outstanding Series A Preferred Stock (the “Required Holders”) expressly consent to the creation of Parity Stock (as defined below) or Senior Preferred Stock (as defined below), all shares of capital stock are junior in rank to all Series A Preferred Stock with respect to the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company (such junior stock is referred to herein collectively as “Junior Stock”). The rights of all such shares of capital stock of the Company will be subject to the rights, powers, preferences and privileges of the Series A Preferred Stock. Without limiting any other provision of this COD, without the prior express consent of the Required Holders, voting separate as a single class, the Company will not hereafter authorize or issue any additional or other shares of capital stock that is (i) of senior rank to the Series A Preferred Stock in respect of the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company (collectively, the “Senior Preferred Stock”), (ii) of pari passu rank to the Series A Preferred Stock in respect of the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company (collectively, the “Parity Stock”) or (iii) any Junior Stock having a maturity date or any other date requiring redemption or repayment of such shares of Junior Stock that is prior to the first anniversary of the December 20, 2021. In the event of the merger or consolidation of the Company with or into another corporation, the Series A Preferred Stock will maintain their relative rights, powers, designations, privileges and preferences provided for herein and no such merger or consolidation will result inconsistent therewith.

 

The Series A Preferred Stock has a liquidation preference equal to an amount per Series A Preferred Stock equal to the sum of (i) the Black Scholes Value (as defined in the Warrants, which was sold concurrent with the Series A Preferred Stock) with respect to the outstanding portion of all Warrants held by such holder (without regard to any limitations on the exercise thereof) as of the date of such event and (ii) the greater of (A) 125% of the Conversion Amount of such Series A Preferred Stock on the date of such payment and (B) the amount per share such holder would receive if such holder converted such Series A Preferred Stock into common stock immediately prior to the date of such payment, and will be entitled to convert into shares of common stock at an initial fixed conversion price of $9.9061 per share, subject to a beneficial ownership limitation of 4.99% which can be adjusted to a beneficial ownership limitation of 9.99% upon sixty-one (61) days’ prior written notice.

 

15

 

 

Under the terms of the COD, the initial fixed conversion price of the Series A Preferred Stock is $9.9061, subject to adjustment. In the event that (i) the average of the VWAP of the Company’s shares for each of the five (5) trading days immediately preceding the date of delivery is less than the fixed conversion price of $9.9061 (a “Price Failure”), or (ii) the sum of (x) the aggregate daily dollar trading volume (as reported on Bloomberg) of our common stock on Nasdaq during the ten (10) trading day period ending on the trading day immediately preceding such date of determination, divided by (y) ten (10), is less than $1,500,000 (a (“Volume Maximum Failure”), each share of Series A Preferred Stock is entitled to convert at a price equal to 90% of the sum of the two (2) lowest VWAPs during the ten (10) trading day period immediately preceding the date of delivery divided by two (2) (the “90% Conversion Price”), but not less than the Floor Price (as defined in the COD), or, at the time of such Price Failure or Volume Maximum Failure, the sum of the average daily U.S. Dollar volume for our common stock during the ten (10) days previous to conversion divided by ten (10) is less than $2 million then each share of Series A Preferred Stock is entitled to convert at the lower of the fixed conversion price or a price equal to 80% of the sum of the two (2) lowest VWAPs during the ten (10) trading day period immediately preceding delivery divided by two (2) (the “80% Conversion Price”), but not less than the Floor Price (such 80% Conversion Price or 90% Conversion Price, as the case may be, the “Alternate Conversion Price”). In addition, the COD provides for an adjustment to the conversion price and exercise of the Warrant in the event of a “new issuance” of our common stock, or common stock equivalents, at a price less than the applicable conversion price of the Series A Preferred Stock or exercise price of the Warrant. The adjustment is a “full ratchet” adjustment in the conversion price of the Series A Preferred Stock equal to the lower of the new issuance price or the then existing conversion price of the Series A Preferred Stock with few exceptions. Furthermore, if we fail to maintain an adequate number of authorized and unissued shares of our common stock in reserve and we are unable to deliver shares or our common stock upon conversion of the Preferred Stock, we may be required to redeem the shares we were unable to deliver at a price equal to the highest closing price of our common stock during the time between the failure to deliver shares of our common stock and the redemption date.

 

If certain defined “triggering events” defined in the COD occur, such as a breach of the Registration Rights Agreement (specifically the Company’s Form S-1 as filed on SEC Edgar on September 13, 2021 and subsequently amended), suspension of trading, or our failure to convert the Series A Preferred Stock into common stock when a conversion right is exercised, failure to issue our common stock when the Warrant is exercised, failure to declare and pay to any holder any dividend on any dividend date, or upon a “bankruptcy triggering event” (as defined in the COD), then we may be required to redeem the Series A Preferred Stock for cash in the amount of up to a minimum of 125% of their Conversion Amount (as defined in the COD). In addition, if thirty (30) days after our common stock commences trading on the Nasdaq Stock Market the sum of the average daily dollar volume for the ten (10) days previous to conversion divided by ten (10) is less than $2.5 million, then the Series A Preferred Stock will be entitled to a one-time dividend equal to an 8% increase in the stated value of the Series A Preferred Stock, or an $80 dollar increase per share in stated value, resulting in a stated value of $1,080 (one thousand and eighty dollars) per Series A Preferred Stock. Additionally, if any of the triggering events are not addressed on a timely basis, we could be liable to pay and 18% per annum dividend. On April 29, 2022, the Company experienced a triggering event as defined in the COD.

 

In the event that the Company experiences a “Change of Control” (as defined in the COD), the Company may also be required to redeem the Preferred Shares for cash at a minimum of 125% of their Conversion Amount.

 

Holders of Series A Preferred Stock will have no voting rights, except as required by law and as expressly provided in the COD.

 

(b) 3i Warrant Terms

 

Concurrently with the issuance of our Preferred Stock, the Company issued warrants to purchase 2,018,958 shares of the Company’s common stock at an exercise price of $9.9061 per share, subject to adjustments (“3i Warrants”). The material terms of the 3i Warrants are as follows:

 

  (i) The warrants have and term of three years and expire on December 20, 2024;

 

  (ii) The exercise of the warrants are subject to a beneficial ownership limitation of 4.99% which can be adjusted to a beneficial ownership limitation of 9.99% upon sixty-one (61) days’ prior written notice;

 

  (iii) The exercise price and the number of 3i Warrant shares issuable upon the exercise of the 3i Warrants are subject to adjustment, as follows:

 

  o In the event of a stock dividend, stock split or stock combination recapitalization or other similar transaction involving the Company’s common stock the exercise price will be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event;

 

16

 

 

  o If the Company sells or issues any shares of common stock, options, or convertible securities at an exercise price less than a price equal to the Warrant exercise price in effect immediately prior to such sale (a “Dilutive Issuance”), then immediately after such Dilutive Issuance, the exercise price then in effect shall be reduced to an amount equal to the new issuance price; 

 

  o Simultaneously with any adjustment to the exercise price, the number of 3i Warrant shares that may be purchased upon exercise of the 3i Warrant shall be increased or decreased proportionately, so that after such adjustment the aggregate exercise price payable hereunder for the adjusted number of 3i Warrant shares shall be the same as the aggregate exercise price in effect immediately prior to such adjustment (without regard to any limitations on exercise) and;

 

  o Voluntary adjustment for the Company to any amount and for any period deemed appropriate by the board of directors of the Company.

 

  (iv) In the event of either the Company consolidating or merging with or into another entity (the “Fundamental Transaction”), the sale or assignment of substantially all of the Company’s subsidiaries, or a Triggering Event (as defined in the COD), the holder is entitled to require the Company to pay the holder an amount in cash equal to the Black-Scholes value of the 3i Warrants on or prior to the later of the second trading after the date of request for payment and the date of consummation of the Fundamental Transaction; or at any time after the occurrence of the Triggering Event.

 

(c) Accounting

 

  i. Series A Convertible Preferred Stock

 

The Company evaluated the Series A Convertible Preferred Stock under ASC 480-10 to determine whether it represents an obligation that would require the Company to classify the instrument as a liability and determined that the Series A Convertible Preferred Stock is not a liability pursuant to ASC 480-10. Management then evaluated the instrument pursuant to ASC 815 and determined that because the holders of the Series A Convertible Preferred Stock may be entitled to receive cash, the Series A Convertible Preferred stock should be recorded as mezzanine equity given the cash redemption right that is within the holder’s control.

 

Generally, preferred stock that are currently redeemable should be adjusted to their redemption amount at each balance sheet date. If it is probable that the equity instrument will become redeemable, the Company has the option to either accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or to recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company recognizes changes in redemption value when redemption becomes probable to occur.

 

  ii. 3i Warrants

 

The 3i Warrants were identified as a freestanding financial instrument and are within the scope of ASC 480-10. Liability-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are recognized through earnings for as long as the contracts continue to be classified as a liability. The measurement of fair value is determined utilizing an appropriate valuation model considering all relevant assumptions current at the date of issuance and at each reporting period (i.e., share price, exercise price, term, volatility, risk-free rate and expected dividend rate).

 

17

 

 

Management further evaluated the financial instrument and all identified features pursuant to ASC 815 and concluded the Warrants would be classified as a liability and subsequently measured at fair value in future reporting periods. Accordingly, a residual fair value method has been applied with respect to the allocation of proceeds between the Preferred Stock and the Warrants. 

 

Between January 1, 2022, and March 31, 2022, a total of 1,973 Series A Preferred shares were converted into 746,276 shares of our common stock, thereby reducing outstanding Series A Preferred shares at March 31, 2022 to 17,827. The fair value of the derivative liability associated with the Series A Preferred Stock converted during the three month period ended March 31, 2022, as determined by Monte Carlo simulations, was $452. Because the latest three conversions in March 2022 were completed at less than the agreed floor price, we recorded a floor price liability of $134 within accrued liabilities and recognized a $134 reduction of additional paid in capital. Additionally, because the Company’s average daily dollar volume of stock trading was less than $2.5 million during a ten-day period in January 2022, the Company has recorded a one-time deemed dividend of 8% in the amount of $1,572 on preferred stock converted between February 1, 2022 and March 31, 2022 and the balance of preferred stock outstanding as at March 31, 2022 as an increase to the value of the convertible preferred stock and a reduction of additional paid in capital.

 

The following inputs were used for the Series A Preferred Stock conversions recorded in the three month period ended March 31, 2022 and the fair value of the Series A Preferred Derivative liability determined at March 31, 2022 and December 31, 2021:

 

   January 1, 2022 –
March 31, 2022
   December 31,
2021
 
Initial exercise price  $9.90   $9.91 
Stock price on valuation date     $1.93 - $10.75       $10.37 
Risk-free rate     1.03% - 2.40%        0.96%
Time to exercise (years)     2.722.96        2.97 
Equity volatility     70%- 90%        70%
Probability of volume failure     93% - 99 %      92%
Rounded 10 day average daily volume (in 1,000’s)     332 - 873        908 

 

On March 31, 2022, the Company utilized the reset strike options Type 2 model by Espen Garder Haug and Black-Scholes Merton models to estimate the fair value of the Warrants to be approximately $2,265. On December 31, 2021, the Company utilized Monte Carlo simulations models to estimate the fair value of the Warrants to be approximately $11,273. The Warrants were valued at March 31, 2022, and December 31, 2021, using the following inputs:

 

   March 31,
2022
   December 31,
2021
 
Initial exercise price  $9.91   $9.91 
Stock price on valuation date  $2.04   $10.50 
Risk-free rate   2.40%   0.91%
Expected life of the Warrant to convert (years)   2.73    3.0 
Rounded annual volatility   110%   73%
Timing of liquidity event   Q4 2022 – Q1 2023    Q3 2022 – Q2 2023 
Expected probability of event   90%   90%

 

18

 

 

The accounting for the Series A Convertible Preferred Stock and Warrants is illustrated in the table below:

 

    Consolidated Balance Sheets     Consolidated
Statement of
Operations &
Comprehensive
Loss
 
    Warrant
liability
    Series A
Preferred
Derivative
Liability
    Series A
Convertible
Preferred
Stock –
Mezzanine
Equity
   

 

 

Common
Stock

    Additional
paid-in
capital
    Finance
Costs
    Fair value
adjustment to
derivative and warrant
liabilities
 
                                           
Subscription proceeds received on December 20, 2021   $ 11,273     $ 7,409     $ 1,318     $     $     $     $  
Costs allocated     (877 )           (679 )                          
Costs expensed     877                               877        
December 21, 2021 conversion of 200 Series A Preferred Stock           (74 )     (7 )     2       80              
Fair value adjustment at December 31, 2021           (154 )                             (154 )
Balances at December 31, 2021   $ 11,273     $ 7,181     $ 632     $ 2     $ 80     $ 877     $ (154 )

 

    Consolidated Balance Sheets     Consolidated
Statement of
Operations &
Comprehensive
Loss
 
    Warrant
liability
    Series A
Preferred
Derivative
Liability
    Series A
Convertible
Preferred
Stock –
Mezzanine
Equity
    Common
Stock
    Additional
paid-in
capital
    Accrued
Liabilities
    Fair value
adjustment to
derivative and warrant
liabilities
 
                                           
Balances at December 31, 2021   $ 11,273     $ 7,181     $ 632     $ 2     $ 80     $     $            —   
Conversion of 1,973 Series A Preferred Stock, net           (452 )     (62 )     75       306       134        
8% deemed dividend on Preferred Stock                 1,572             (1,572 )            
Fair value adjustment at March 31, 2022     (9,008 )     (3,558 )                             12,566  
    $ 2,265     $ 3,171     $ 2,142     $ 77     $ (1,186   $ 134      $ 12,566  

 

13. Derivative Liabilities

 

(a) Series A Preferred Stock Conversion Feature

 

The derivative scope exception under ASC 815 is not met because a settlement contingency is not indexed to the Company’s stock. Therefore, the redemption feature (derivative liability) has been bifurcated from the Series A Preferred Stock and recorded as a derivative liability. The derivative value of the Series A Preferred Stock Redemption Feature (the “Redemption Feature”) is the difference between the fair value of the Series A Preferred Stock with the Redemption Feature and the Series A Preferred Stock without the Redemption Feature. The Series A Preferred Stock Redemption Feature has been valued with a Monte Carlo Simulation model, using the inputs as described in Note 12(c) ii.

 

19

 

 

 

(b) Investor Warrants

 

The Company did not issue any investor warrants during the three-month period ended March 31, 2022, and no investor warrants were outstanding.

 

At March 31, 2021 the Company had a total of 1,086,759 investor warrants outstanding and exercisable at a weighted average exercise price of $36.0 per share. No investor warrants were granted, exercised, or expired during the three-month period ended March 31, 2021.

 

(b) Valuation of Derivative Liabilities

 

The derivative liabilities are measured at fair value at each reporting period and the reconciliation of changes in fair value is presented in the following tables:

 

   3i Fund Series A
Redemption
Feature
   Settlement
Warrants
   TO2
Warrants
 
   March 31,
2022
$
   March 31,
2021
$
   March 31,
2021
$
 
Balance beginning   7,181    102    47 
Issued during the period   
    
    
 
Change in fair value   (3,558)   (7)   (38)
Translation effect   
        
 
Amount transferred to Equity   (452)   
    
 
Balance – end of period   3,171    95    9 
Fair value per warrant / Series A Preferred share issuable at period end   177.88    0.02    0.0 

 

14. Stockholders’ Equity

 

During the three months ended March 31, 2022, the Company issued 746,276 shares of common stock valued at $381, net of the $134 floor price adjustment payable (see Note 12 (c), upon the conversion of 1,973 shares of Series A Preferred.

 

During the three months ended March 31, 2021, the Company issued 528,810 common shares valued at $2,384 on conversion of debt.

 

20

 

 

15. Stock-based payments

 

During the three months ended March 31, 2022, the total stock-based payment expenses recorded in the condensed consolidated statement of operations and comprehensive loss were $1,065 (2021: $195) of which $703 and $362 are recognized as general and administrative and research and development expenses respectively (2021: $129 as general and administrative and $66 as research and development expenses respectively). Total compensation cost of $3,380 for non-vested warrants as at March 31, 2022 and is expected to be realized over a period of 2.3 years.

 

A summary of stock option activity under the Company’s stock option plans during the three-month period ended March 31, 2022, is presented below:

 

   Options Outstanding 
   Number of
Shares
   Weighted
Average
Exercise 
Price Share
   Weighted
Average
Life (in years)
 
Outstanding December 31, 2021   1,174,992   $      6.8    4.9 
Granted            
Exercised            
Cancelled or expired            
Outstanding as of March 31, 2022   1,174,992   $6.8    4.7 
Options exercisable at March 31, 2022   635,475   $7.6    4.5 

 

During the three-month period ended March 31, 2021, no options were granted, exercised, expired, or cancelled.

 

16. Segments

 

The Company is domiciled in the United States of America and its operations are in Denmark and operates as one operating segment. Our Chief Executive Officer (CEO), as the chief operating decision-maker, manages and allocates resources to the operations of our Company on a total Company basis. Managing and allocating resources on a total company basis enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with our long-term company-wide strategic goals. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources, and setting incentive targets. The Company has neither revenues from external customers outside Denmark, nor long-term assets in geographical areas other than Denmark.

 

17. Loss per share of common stock

 

Basic loss per share is derived by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants and stock options, which would result in the issuance of incremental shares of common stock unless such effect is anti-dilutive. In calculating the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remained the same for both calculations because when a net loss exists, dilutive shares are not included in the calculation. Potentially dilutive securities outstanding, as determined by the latest applicable conversion price, that have been excluded from diluted loss per share due to being anti-dilutive include the following:

 

   March 31,   March 31, 
   2022    2021 
Warrants and stock options   3,193,950    1,301,878 
Series A Convertible Preferred stock   9,717,929    
 
Convertible debt   
    114,076 
    12,911,879    1,415,954 

 

21

 

 

18. Financial Instruments

 

The following tables present information about the Company’s financial instruments measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:

 

   Fair Value Measurements as of March 31, 2022
Using:
 
   Level 1   Level 2   Level 3   Total 
Assets:                
Investment  $314   $
   $
   $314 
Liabilities:                    
Warrant liability  $
   $
   $(2,265)  $(2,265)
Series A Convertible Preferred Stock Redemption Feature   
    
    (3,171)   (3,171)
   $
   $
   $(5,436)  $(5,436)

 

   Fair Value Measurements as of December 31, 2021
Using:
 
   Level 1   Level 2   Level 3   Total 
Assets:                
Investment  $350   $   $   $350 
Liabilities:                    
Warrant liability  $   $   $(11,273)  $(11,273)
Series A Convertible Preferred Stock Redemption Feature           (7,181)   (7,181)
   $   $   $(18,454)  $(18,454)

 

Methods used to estimate the fair values of our financial instruments, not disclosed elsewhere in these financial statements, are as follows:

 

When available, our marketable securities are valued using quoted prices for identical instruments in active markets. If we are unable to value our marketable securities using quoted prices for identical instruments in active markets, we value our investments using broker reports that utilize quoted market prices for comparable instruments. Accordingly, our investment is considered a Level 1 financial asset. We have no financial assets or liabilities measured using Level 2 inputs. Financial assets and liabilities are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable.

 

The Company recognizes its derivative liabilities as level 3 and values its derivatives using the methods discussed below. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using terms in the notes that are subject to volatility and market price of the underlying common stock of the Company.

 

The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s policy is to recognize transfers into and out of levels within the fair value hierarchy at the date the actual event or change in circumstances that caused the transfer occurs. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. There were no transfers between level 1 or level 2 during the three-month periods ended March 31, 2022, or March 31, 2021.

 

22

 

 

The Company used the reset strike options Type 2 model by Espen Garder Haug and Black-Scholes Merton models to measure the fair value of the warrant liability at $2,265 on March 31, 2022 and Monte Carlo simulations models to measure the fair value at $11,273 on December 31, 2021. The Company used Monte Carlo simulation models to measure the fair value of the Series A convertible preferred stock redemption feature at $3,171 and $7,181 respectively on March 31, 2022 and December 31, 2021, and will subsequently remeasure the fair value at the end of each period and record the change of fair value in the Condensed Consolidated Statements of Operation and Comprehensive Loss during the corresponding period. Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. During the three-month period ended March 31, 2022, the Company’s stock price decreased from initial valuation. As the stock price decreases for each of the related derivative instruments, the value to the holder of the instrument generally decreases. Stock price is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments.

 

19. Income Taxes

 

The effective tax rate for the three-month periods ended March 31, 2022, and March 31, 2021, was impacted by unbenefited losses. Specifically, the March 31, 2022, impairment charge of approximately $14,000 has resulted in a tax benefit of $1,227 in the three months ended March 31, 2022.

 

20. Commitments and Contingencies

 

a) Development costs

 

Under the terms of the June 2020 Out-License agreement, the Company is liable for development costs of Smerud Medical Research International (“Smerud”) in the approximate amount of $1,264 (one million two hundred and sixty-four thousand) which has been accrued as of December 31, 2021, and is payable as Smerud was unable to identify investors to fund development of in-licensed products from the Company by December 31, 2021.

 

Subsequent to December 31, 2021, and pursuant to the terms of the March 28, 2022, Amended License Agreement, the $1,309 liability was forgiven in exchange for a payment to LiPlasome. Consequently, as at March 31, 2022, the Company recognized a gain on sale of IP of $971 thousand and recorded a balance due to LiPlasome of $338 thousand (2,273 thousand DKK) in accrued liabilities, which was paid on April 1, 2022. However, notwithstanding the termination of the out-license agreement, we are currently engaged in discussions with Smerud in connection with the further development of 2X-111.

 

b) Oncoheroes

 

Effective January 2, 2022, the Company entered into an Exclusive License Agreement with Oncoheroes Biosciences Inc. (the “Oncoheroes Agreement”) to grant Oncoheroes an exclusive royalty-bearing global license to both dovitinib and stenoparib in pediatric cancers. Oncoheroes will take responsibility for pediatric cancer clinical development activities for both clinical-stage therapeutics. Allarity will support Oncoheroes’ pediatric clinical trials by providing clinical-grade drug inventory at cost and by facilitating DRP® companion diagnostic screening of pediatric patients for each drug. Under the licenses, Oncoheroes will receive commercialization rights for pediatric cancers, subject to the Company’s first buy-back option for each program, and the Company will receive an upfront license fee and regulatory milestones for each program, specifically one for dovitinib and one for stenoparib, as follows:

 

  i. a one-time upfront payment of $250 thousand and $100 thousand for stenoparib and dovitinib respectively, within 5 business days after January 2, 2022 ($350 thousand received as of January 11, 2022 and recorded as a gain on sale of IP); and

 

  ii. two milestone payments of $1,000 (one million) each due and payable upon receipt of regulatory approval of a product in the United States, and of a product in Europe, respectively.

 

Pursuant to the Oncoheroes Agreement Allarity is also entitled to tiered royalties on aggregate net product sales (“Sales”) of between 7% and 12% on net sales of products as follows: 7% on Sales less than $100 million; 10% on Sales of greater than $100 million and less than $200 million; and 12% on Sales greater than $200 million.

 

23

 

 

d). Lantern Pharma, Inc. – Irofulven Agreement

 

On July 23, 2021, we entered into an Asset Purchase Agreement with Lantern Pharma, Inc. relating to our inventory of Irofulven active pharmaceutical ingredients, our clinical research data relating to Irofulven developed by us during the drug development program under the May 2015 Drug License and Development Agreement for Irofulven and terminated our obligation to further advance the development of Irofulven under the May 2015 agreement. Under the Asset Purchase Agreement, Lantern Pharma agreed to pay us $1 million on closing of the transaction, and additional amounts:

 

  (i) when the inventory of Irofulven API is recertified with a longer shelf life;

 

  (ii) upon the initiation of treatment of the first patient in an investigator-led “compassionate use” ERCC2/3 mutation subgroup study using Irofulven in certain agreed upon investigators;

 

  (iii) upon the initiation of treatment of the first patient within twenty-four months after the closing of the transaction in any human clinical trial of Irofulven initiated by Lantern Pharma; and
     
  (iv) upon the initiation of treatment of the second patient within an agreed upon time period after the closing of the transaction in any human clinical trial of Irofulven initiated by Lantern Pharma.  

 

Effective March 18, 2022, pursuant to clause (i) the inventory was recertified with a longer shelf life and as of March 31, 2022, we received $459 thousand which has been recorded as a gain on sale of IP.

 

21. Subsequent Events

 

For its interim consolidated financial statements as of March 31, 2022, and for the three months then ended, the Company evaluated subsequent events through the date on which those financial statements were issued.

 

i. Series A Preferred Stock Triggering Event

 

As more specifically discussed below, a “Triggering Event” under the COD occurred on April 29, 2022, under Section 5(a)(ii) of the COD, which would have resulted in the following unless 3i, LP agreed to forebear and/or waive its rights under the COD:

 

1. An 18% per annum dividend will start to accrue on the stated value of all outstanding Preferred Shares and will continue to accrue until the Triggering Event has been cured. The accrued dividend is added to the stated value prior to the Dividend Payment Date and paid in cash on the first trading day of the Company’s next fiscal quarter. A “Late Charge” in the amount of 18% per annum will accrue on any amounts due to be paid to holders of the Preferred Shares if not paid when due, including payments that may be owed under Section 2(e) of the Registration Rights Agreement (“RRA”).

 

2. A “Triggering Event Redemption Right” will commence and remain open for a period of 20 trading days from the later of the date the Triggering Event is cured or the receipt by 3i, LP of the Triggering Event Notice. Under the Triggering Event Redemption Right, if elected by the holder of the Preferred Shares, the Company would be obligated to redeem all or a portion of the Preferred Shares for a minimum of 125% of the stated value of the Preferred Shares. Concurrently, under the provisions of the PIPE Warrant, if elected by 3i, the Company would be obligated to redeem the PIPE Warrant for the Black Sholes Triggering Event Value as defined in the warrant agreement.

 

24

 

 

3. A “Registration Delay Payment” will accrue on April 22, 2022 (the expiration of the Allowable Grace Period under the RRA) in the amount of 2% of 3i, LP’s “Purchase Price” as defined in the Securities Purchase Agreement which is approximately 2% of $20 million, or $400 thousand and will continue to accrue at 2% every 30 days thereafter. Additionally, a late charge of 2% per month will accrue on any payments that are not paid when due. The Registration Delay Payments will stop accruing when the post-effective amendment is declared effective by the SEC at which time the registration statement and its prospectus will again be available for the resale of common stock.

 

On May 4, 2022, the Company and 3i, LP entered into a Forbearance Agreement and Waiver, dated April 27, 2022, wherein 3i, LP confirmed that no Triggering Event as defined under the COD has occurred prior to April 27, 2022, that a Triggering Event under Section 5(a)(ii) will and has occurred on April 29, 2022, and that in consideration for the Registration Delay Payments the Company is obligated to pay under the RRA, and additional amounts the Company is obligated to pay under the COD and 3i, LP’s legal fees incurred in the preparation of the Forbearance Agreement and Waiver in the aggregate of $538,823.00 paid upon execution of the Forbearance Agreement and Waiver, and so long as the Company pays the Registration Delay Payments that become due and payable under the RRA after the execution of the Forbearance Agreement and Waiver, 3i, LP has agreed to forbear exercising any rights or remedies that it may have under the COD that arises as a result of a Triggering Event under Section 5(a)(ii) of the COD and Section 4(c)(ii) of the PIPE Warrant until the earlier to occur of (i) the date immediately prior to the date of occurrence of a Bankruptcy Triggering Event, (ii) the date of occurrence of any other Triggering Event under Section 5(a) of the COD (excluding any Triggering Event arising solely as a result of Section 5(a)(ii) of the COD and Section 4(c)(ii) of the PIPE Warrant), (iii) the time of any breach by the Company under the Forbearance Agreement and Waiver, (iv) the Resale Availability Date as defined therein and (v) June 4, 2022 (such period, the “Forbearance Period”). Provided that the Company is not in breach of its obligations under Forbearance Agreement and Waiver, effective as of the Trading Day immediately following the date the Company cures the Triggering Event under Section 5(a)(ii) of the COD, 3i, LP agrees to waive any rights or remedies that it may have under the COD that arises as a result of a Triggering Event under Section 5(a) of the COD and Section 4(c)(ii) of the PIPE Warrant that may have arisen prior to the date of the Forbearance Agreement and Waiver.

 

ii. Series A Preferred Stock Conversions

  

On May 25, 2022, 3i, LP converted a total of 809 Series A Preferred shares into 441,005 shares of our common stock. Pursuant to the terms of the COD, because the Alternate Conversion Price was below the Floor Price of $1.9812, the Company is obligated to pay 3i, LP an Alternate Conversion Floor Amount of $1,377 which has been recorded as a liability and reduction to additional paid in capital as of May 27, 2022. In addition, under the terms of the RRA, the Company also paid 3i, LP an additional $400 in Registration Delay Payments.

 

25

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

You should read the following discussion and analysis of our financial condition and plan of operations together with our condensed consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from the plans, intentions, expectations and other forward-looking statements included in the discussion below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those factors discussed in the section titled “Risk Factors” of our Annual Report on Form 10-K, filed with the SEC on May 17, 2022.

 

Overview

 

We are a biopharmaceutical company focused on discovering and developing highly targeted anti-cancer drug candidates. Through the use of its Drug Response Predictor (DRP®) platform, the Company identifies the value in drug assets that have otherwise been discontinued by identifying patient populations where these drugs are active. The Company’s three lead drug candidates are: the tyrosine kinase inhibitor (TKI) dovitinib, the poly-ADP-ribose polymerase (PARP) inhibitor stenoparib, and the microtubule inhibitor agent IXEMPRA.

 

Risks and Uncertainties

 

The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel and collaboration partners, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations, and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval prior to commercialization. Even if the Company’s research and development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.

 

Impacts of COVID-19 on our Business — Update

 

In March 2020, the World Health Organization declared COVID-19 a global pandemic. COVID-19 has had an impact on our operations as it caused some unexpected delays in our clinical program activities as clinical trials were delayed. Management is unable to estimate the future financial effects, if any, to our business as a result of COVID-19 because of the high level of uncertainties and unpredictable outcomes of this disease.

 

We are continuing to evaluate the impact of COVID-19 pandemic on our business and are taking proactive measures to protect the health and safety of our employees, as well as to maintain business continuity. Based on guidance issued by federal, state and local authorities, we transitioned to a remote work model for our employees, effective March 16, 2020. During the recent months restrictions due to COVID-19 have lifted significantly and as a result, our Danish employees have returned to work. Our North American employees are continuing to work remotely. We will continue to closely monitor and seek to comply with guidance from governmental authorities and adjust our activities as appropriate.

 

The ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trial, healthcare systems or the global economy. However, these effects could harm our operations, and we will continue to monitor the COVID-19 situation closely.

 

26

 

 

Impact of the Russia-Ukraine War — Update

 

There have been immense flows of refugees to Europe and Denmark is ready to facilitate and to accept refugees from the Ukraine. It is far too early to estimate how many migrants Denmark will facilitate, but immigration officials have begun preparing to accept Ukrainian refugees. Being a North Atlantic Treaty Organization (NATO) member, Denmark will strengthen its own national preparedness as well as that of the NATO defense alliance. The Ukraine crisis has become a new a destabilizing factor in the Danish and global economy. It dampens growth and increases inflation at a time when inflation and capacity utilization is already high. While the Danish economy is generally robust and able to handle new challenges, and it is expected to enter a pause in growth. However, there are risks of a fall in activity in the Danish economy in general. To date the War has not yet had an impact on our results of operations however we expect it may have an impact on the costs of materials we purchase for our laboratory operations in Denmark but, we cannot predict or quantify the impact now.

 

Financial Operations Overview

 

Since our inception in September of 2004, we have focused substantially all our resources on conducting research and development activities, including drug discovery and preclinical studies, establishing, and maintaining our intellectual property portfolio, the manufacturing of clinical and research material, hiring personnel, raising capital and providing general and administrative support for these operations. In recent years, we have recorded very limited revenue from collaboration activities, or any other sources. We have funded our operations to date primarily from convertible notes and the issuance and sale of our ordinary shares.

 

We have incurred net losses in each year since inception. Our net losses were $3.1 million and $3.1 million for the three months ended March 31, 2022, and March 31, 2021, respectively. As of March 31, 2022, we had an accumulated deficit of $69.6 million. Substantially all our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect to continue to incur significant expenses and increasing operating losses over at least the next several years. We expect our expenses will increase substantially in connection with our ongoing activities, as we:

 

  advance drug candidates through clinical trials;
     
  pursue regulatory approval of drug candidates;

 

  operate as a public company;
     
  continue our preclinical programs and clinical development efforts;
     
  continue research activities for the discovery of new drug candidates; and
     
  manufacture supplies for our preclinical studies and clinical trials.

 

Components of Operating Expenses

 

Research and Development Expenses

 

Research and development expenses include:

 

  expenses incurred under agreements with third-party contract organizations, and consultants;
     
  costs related to production of drug substance, including fees paid to contract manufacturers;
     
  laboratory and vendor expenses related to the execution of preclinical trials; and
     
  employee-related expenses, which include salaries, benefits and stock-based compensation.

 

27

 

 

We expense all research and development costs in the periods in which they are incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks and estimates of services performed using information and data provided to us by our vendors and third-party service providers. Non-refundable advance payments for goods or services to be received in future periods for use in research and development activities are deferred and accounted for as prepaid expenses. The prepayments are then expensed as the related goods are delivered and as services are performed.

 

To date, most of these expenses have been incurred to advance our lead drug candidates, dovitinib, stenoparib, and IXEMPRA®.

 

We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our drug candidates, as our drug candidates advance into later stages of development, and as we continue to conduct clinical trials. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our drug candidates is highly uncertain. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our drug candidates.

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of personnel-related costs, facilities costs, depreciation and amortization expenses and professional services expenses, including legal, human resources, audit, and accounting services. Personnel-related costs consist of salaries, benefits, and stock-based compensation. Facilities costs consist of rent and maintenance of facilities. We expect our general and administrative expenses to increase for the foreseeable future due to anticipated increases in headcount to advance our drug candidates and as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, Nasdaq Stock Market, additional insurance expenses, investor relations activities and other administrative and professional services.

 

Results of Operations for the Three Months Ended March 31, 2022, and March 31, 2021 (unaudited)

 

The following table summarizes our results of operations for the three months ended March 31, 2022, and 2021:

 

   For the Three Months
Ended
March 31,
   Increase/ 
   2022   2021   (Decrease) 
   (In thousands)     
Operating expenses:            
Research and development  $1,289   $1,251   $38 
Impairment of intangible assets   14,007        14,007 
General and administrative   3,013    1,211    1,802 
Total operating expenses   18,309    2,462    15,847 
Loss from operations:  $(18,309)  $(2,462)  $(15,847)

 

28

 

 

Research and Development Expenses

 

We currently do not track our research and development costs by product candidate. A breakdown by nature of type of expense for the three months ended March 31, 2022, and 2021 is provided below.

 

   For the three months
ended
March 31,
   Increase/ 
   2022   2021   (Decrease) 
   (In thousands)     
Research study expenses  $505   $769   $(264)
Recovery of R&D costs       (11)   11 
Tax credit   (454)   (219)   (235)
Manufacturing & supplies   168    71    97 
Contractors   377    216    161 
Patents   76    60    16 
Staffing   609    314    295 
Amortization   20    36    (16)
Other   (12)   15    (27)
   $1,289   $1,251   $38 

 

For the three months ended March 31, 2022, compared to March 31, 2021

 

The increase of $38 thousand in research and development expenses was primarily because staffing increased $295 thousand due to employee stock-based compensation expenses and contractors increased $161 thousand as the Company prepared for our FDA meeting in May. Manufacturing increased $97 thousand due to ongoing validation of our manufacturing of our priority drugs. Recovery of R&D costs decreased by $11 thousand, patent costs increased by $16 thousand, and increased tax credits of $235 thousand offset expenses. This was offset by a decrease of $264 thousand in research study expenses as our clinical activity is limited to two of our three top priority assets, a decrease of $16 thousand in amortization, and a decrease of $27 thousand in other expenses.

 

Impairment of Intangible Assets

 

As a result of both the Company’s February 15, 2022, receipt of a RTF from the U.S. Food and Drug Administration regarding the Company’s NDA for Dovitinib, and the current depressed state of the Company’s stock price, the Company has performed an impairment assessment on its individual intangible assets utilizing a discounted cash flow model and recognized an impairment charge of $14.0 million during the three months ended March 31, 2022.

 

General and Administrative Expenses

 

General and administrative expenses increased by $1.8 million for the three months ended March 31, 2022, compared to March 31, 2021. The increase was primarily due to an increase in professional fees of $647 thousand, staffing expense of $634 thousand, insurance of $342 thousand, premises of $4 thousand, listings expenses of $91 thousand, communications expenses of $15 thousand, and other administrative expenses of $69 thousand.

 

Other Income (Expenses), Net

 

For the three months ended March 31, 2022, compared to March 31, 2021

 

Other income (expense) of $14.0 million recognized in the three months ended March 31, 2022, consisted primarily of a $12.6 million fair value adjustment to derivative   and warrant liabilities and income of $1.8 million from the gain on sale of IP, offset by ($269) thousand in foreign exchange losses, ($39) thousand in interest expenses, and ($36) thousand loss on investment.

  

29

 

 

For the three months ended March 31, 2021, other expense of ($590) thousand consisted of finance expenses of ($87) thousand, loss on extinguishment of convertible debt of ($116) thousand, loss on investment of ($113) thousand, change in fair value of convertible debt of ($201) thousand, foreign exchange losses of ($39) thousand, change in fair value adjustment of derivative liability of $45 thousand, and interest expenses of ($79) thousand. 

 

Changes in fair value of our derivative liabilities and convertible debt are measured using level 3 inputs as described in our condensed consolidated financial statements.

 

Liquidity, Capital Resources and Plan of Operations

 

Since our inception through March 31, 2022, our operations have been financed primarily by the sale of convertible promissory notes and the sale and issuance of our ordinary shares. As of March 31, 2022, we had $14.5 million in cash, and an accumulated deficit of $69.6 million.

 

Our primary use of cash is to fund operating expenses, which consist of research and development as well as regulatory expenses related to our lead drug candidate, dovitinib, and clinical programs for stenoparib and IXEMPRA®, and to a lesser extent, general and administrative expenses. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.

 

As of March 31, 2022, the Company’s cash deposits of $14.5 million were determined to be insufficient to fund its current operating plan and planned capital expenditures for the next 12 months. These conditions give rise to a substantial doubt over the Company’s ability to continue as a going concern.

 

Management’s plans to mitigate the conditions or events that raise substantial doubt include additional funding through public equity, private equity, debt financing, collaboration partnerships, or other sources. There are no assurances, however, that the Company will be successful in raising additional working capital, or if it is able to raise additional working capital, it may be unable to do so on commercially favorable terms. The Company’s failure to raise capital or enter into other such arrangements when needed would have a negative impact on its business, results of operations and financial condition and its ability to develop its product candidates.

 

We expect to incur substantial expenses in the foreseeable future for the development and potential commercialization of our drug candidates and ongoing internal research and development programs. At this time, we cannot reasonably estimate the nature, timing, or aggregate amount of costs for our development, potential commercialization, and internal research and development programs. However, to complete our current and future preclinical studies and clinical trials, and to complete the process of obtaining regulatory approval for our drug candidates, as well as to build the sales, marketing, and distribution infrastructure that we believe will be necessary to commercialize our drug candidates, if approved, we may require substantial additional funding in the future.

 

Contractual Obligations and Commitments

 

We enter into agreements in the normal course of business with vendors for preclinical studies, clinical trials and other service providers for operating purposes. We have not included these payments in the table of contractual obligations above since these contracts are generally cancellable at any time by us following a certain period after notice and therefore, we believe that our non-cancellable obligations under these agreements are not material.

 

30

 

 

Cash Flows

 

The following table summarizes our cash flows for the periods indicated:

 

   For the three months
ended
March 31,
 
   2022   2021 
   (In thousands) 
Net cash flows used in operating activities  $(5,755)  $(2,567)
Net cash flows provided by investing activities   809     
Net cash flows provided by financing activities       2,325 
Effect of foreign exchange rates on cash   (65)   49 
Net (decrease) in cash   (5,011)  $(193)

 

Operating Activities

 

For the three months ended March 31, 2022, net cash used in operating activities was approximately $5.8 million compared to approximately $2.6 million for the three months ended March 31, 2021. The $3.2 million increase in net cash used in operating activities was primarily the result of a $5 thousand decrease in loss offset by a net decrease in current assets and liabilities of $2.2 million, and a net decrease in non-cash expenditures of $1.0 million. 

 

Investing Activities

 

For the three months ended March 31, 2022, net cash provided by investing activities was approximately $809 thousand compared to $0 for the three months ended March 31, 2021. The increase in net cash provided by investing activities was primarily due to proceeds from the sale of IP during the three months ended March 31, 2022.

 

Financing Activities

 

In the three months ended March 31, 2022, we did not receive cash from financing activities. In the three months ended March 31, 2021, we received $2.3 million from financing activities inclusive of $35 thousand from a line of credit, $1.1 million from a convertible loan, and $1.2 million from loan proceeds.

 

Operating Capital and Capital Expenditure Requirements

 

We believe that our existing cash and cash equivalents as of May 27, 2022, and our anticipated expenditures and commitments for the next twelve months, will not enable us to fund our operating expenses and capital expenditure requirements for at least twelve months from the date of this report. Our estimate as to how long we expect our cash to be able to continue to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned.

 

Off-Balance Sheet Arrangements

 

The Company does not have any off-balance sheet arrangements.

 

31

 

 

Critical Accounting Policies and Significant Judgments and Estimates

 

Our management’s discussion and analysis of financial condition and results of operations is based upon our unaudited condensed consolidated financial statements for the three months ended March 31, 2022, and March 31, 2021, and our audited consolidated financial statements for the years ended December 31, 2021, and December 31, 2020, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses. On an on-going basis, we evaluate our critical accounting policies and estimates. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions.

 

Our significant accounting policies are described in the notes to our consolidated financial statements for the years ended December 31, 2021, and December 31, 2020, included in our Form 10-K for the year ended December 31, 2021, filed on May 17, 2022, and there have been no significant changes to our significant accounting policies during the three months ended March 31, 2022. These unaudited interim condensed financial statements should be read in conjunction with the Company’s audited financial statements and accompanying notes.

 

Recently Issued Accounting Pronouncements

 

See the sections titled “Recently adopted accounting pronouncements” in Note 2(dd) and “Recently issued accounting pronouncements not yet adopted” in Note 2(ee) to the Company’s consolidated financial statements for the year ended December 31, 2021, and December 31, 2020, respectively, appearing in the Company’s 10-K filed with the SEC on May 17, 2022; and in Notes 2(i) and 2(j) to the Company’s unaudited condensed consolidated financial statements for the three months ended March 31, 2022 and March 31, 2021.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

As a Smaller Reporting Company, we are exempt from the requirements of Item 3.

 

Item 4. Controls and Procedures.

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2022. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

 

32

 

 

Based on the evaluation of our disclosure controls and procedures as of March 31, 2022, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, because (i) of the material weaknesses identified in our internal controls over financial reporting; and (ii) we were required to restate our financial statements for the year ended December 31, 2020, and quarterly period ended September 30, 2021, which delayed the filing of or required an amendment to our SEC reports, our disclosure controls, and procedures, as defined above, were not effective.

 

As a newly reporting company under the Exchange Act, we are not required to evaluate the effectiveness of our internal controls over financial reporting until the end of the fiscal year after we file our first annual report on Form 10-K, which will occur on December 31, 2022. However, in connection with the audit of our financial statements for the years ended December 31, 2021 and 2020, we identified material weaknesses in our internal controls over financial reporting because we did not have a formal process for period end financial closing and reporting, we historically had insufficient resources to conduct an effective monitoring and oversight function independent from our operations and we lack accounting resources and personnel to properly account for accounting transactions such as the issuance of warrants with a derivative liability component. In particular, the material weaknesses identified were:

 

  a lack of accounting resources required to fulfill US GAAP and SEC reporting requirements;
     
  a lack of comprehensive US GAAP accounting policies and financial reporting procedures and personnel;
     
  a lack of adequate procedures and controls to appropriately account for accounting transactions including liability and the valuation allowance on the deferred tax asset relating to the net operating losses; and
     
  a lack of segregation of duties given the size of our finance and accounting team.

 

We have implemented and are continuing to implement various measures to address the material weaknesses identified; these measures include:

 

  the hiring of a chief financial officer that is a CPA in the U.S.;
     
  The hiring of a Director of Financial Reporting, a CPA (Illinois) who is experienced with public company reporting and is conversant in US GAAP and SEC accounting issues. With this hire we are addressing our ongoing development of our comprehensive US GAAP accounting policies, financial reporting procedures and internal controls over financial reporting;
     
  retaining consulting services to assist with the accounting treatment of complex financial instruments and tax; and
     
  engaged independent US GAAP consulting firm.

 

A significant deficiency is a control deficiency, or a combination of control deficiencies, that adversely affects our ability to initiate, authorize, record, process, or report external financial data reliably in accordance with US GAAP such that there is more than a remote likelihood that a misstatement of our annual or interim financial statements that is more than inconsequential will not be prevented or detected by our employees.

 

A material weakness is a significant deficiency, or combination of significant deficiencies, that results in more than a remote likelihood that a material misstatement of our annual or interim financial statements will not be prevented or detected by our employees. In response, we have begun the process of evaluating our internal control over financial reporting and to address the material weaknesses identified.

 

We intend to continue to take steps to remediate the material weaknesses described above and further evolve our accounting processes, controls, and reviews. We plan to continue to assess our internal controls and procedures and intend to take further action as necessary or appropriate to address any other matters we identify or are brought to our attention.

 

We believe we are making progress toward achieving the effectiveness of our internal controls and disclosure controls. The actions that we are taking are subject to ongoing senior management review, as well as audit committee oversight. We will not be able to conclude whether the steps we are taking will fully remediate the material weaknesses in our internal controls over financial reporting until we have completed our remediation efforts and subsequent evaluation of their effectiveness. We may also conclude that additional measures may be required to remediate the material weaknesses in our internal controls over financial reporting, which may necessitate further action.

 

Changes in Internal Control Over Financial Reporting

 

There have been no changes in the Company’s internal controls over financial reporting during the quarter ended March 31, 2022, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting other than as described above.

 

33

 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings

 

From time to time in the future, we may become involved in litigation or other legal proceedings that arise in the ordinary course of business. We are not currently party to any legal proceedings, and we are not aware of any pending or threatened litigation against us that we believe could have a material adverse effect on our business, operating results or financial condition. In the event we are subject to a legal proceeding, it could have a material adverse impact on us because of litigation costs and diversion of management resources.

 

Item 1A. Risk Factors.

 

An investment in our common stock involves a high degree of risk. You should carefully consider the risks set forth in the section captioned “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on May 17, 2022, before making an investment decision. If any of the risks occur, our business, financial condition or results of operations could suffer. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment. You should read the section captioned “Forward Looking Statements” above for a discussion of what types of statements are forward-looking statements, as well as the significance of such statements in the context of this report.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

Pursuant to the Securities Purchase Agreement with 3i, LP, a Delaware limited partnership (the “Investor”), we issued 20,000 shares of our Series A Preferred Stock and a warrant to purchase 2,018,958 shares of common stock at an initial exercise price of $9.9061 to the Investor along with a PIPE Warrant, for an aggregate purchase price of $20 million. Simultaneously with the execution of the SPA, we also entered into a Registration Rights Agreement with the Investor wherein we agreed to register a number of shares of our common stock equal to the maximum number of shares of our common stock that could be issued upon conversion of the Series A Preferred Stock using a conversion price equal to 20% of $80,000,000 divided by the number of shares of common stock then outstanding (the “Floor Price”) plus 125% of the shares of common stock issuable upon exercise of the PIPE Warrant, or a maximum of 12,618,590 shares of our common stock.

 

From January 1, 2022, to May 27, 2022, pursuant to a series of exercise of conversion by the Investor, we issued 1,187,281 shares of Common Stock to the Investor upon the conversion of 2,782 shares of Series A Preferred Stock (“Conversion Shares”). No proceeds were received by the Company upon such conversion. As of May 27, 2022, we had 17,018 shares of Series A Preferred Stock issued and outstanding.  

  

The offers, sales, and issuances of the Conversion Shares, Series A Preferred Stock and PIPE Warrant to the Investor described above were deemed to be exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act or Rule 506 of Regulation D promulgated thereunder as transactions by an issuer not involving a public offering. Each of the recipients of securities in these transactions was an accredited investor within the meaning of Rule 501 of Regulation D under the Securities Act.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

None.

 

34

 

 

Item 6. Exhibits

 

The following exhibits are filed as part of this Report.

 

Exhibit No.   Description
10.1†(c)   Exclusive License Agreement with Oncoheroes Bioscience, Inc. dated January 2, 2022 (Stenoparib)
10.2†(c)   Exclusive License Agreement with Oncoheroes Bioscience, Inc. dated January 2, 2022 (Dovitnib)
10.3†(c)   Amended and Restated License Agreement among Allarity Therapeutics Europe ApS, LiPlasome Pharma ApS, and Chosa ApS dated March 28, 2022
10.4†(c)   Support Agreement between Allarity Therapeutics A/S and LiPlasome Pharma ApS, dated March 28, 2022
10.5(a)   First Amendment to License Agreement between Novartis Pharma Ag and Allarity Therapeutics Europe ApS
10.6(a)   Convertible Promissory Note
10.7(b)   Forbearance Agreement and Waiver
31.1*   Certifications of the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act
31.2*   Certifications of the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act
32.1*   Certifications of the Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act
32.2*   Certifications of the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act
101.INS*   Inline XBRL Instance Document.
101.SCH*   Inline XBRL Taxonomy Extension Schema Document.
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104*   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

(a) Incorporated by reference from Form 8-K filed with the SEC on April 18, 2022.
(b) Incorporated by reference from Form 8-K filed with the SEC on May 6, 2022.
(c) Incorporated by reference from Form 10-K filed with the SEC on May 17, 2022.

 

Certain portions of this exhibit are omitted because they are not material and would likely cause competitive harm to the registrant if disclosed.

 

*Filed herewith.

 

35

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

ALLARITY THERAPEUTICS, INC.,

A Delaware Corporation

   
Date: May 27, 2022 By: /s/ Steve Carchedi 
    Name:  Steve Carchedi
    Title: Chief Executive Officer
(Principal Executive Officer)
   
Date: May 27, 2022 By: /s/ Jens Erik Knudsen 
    Name: Jens Erik Knudsen
    Title: Chief Financial Officer
(Principal Financial and Accounting Officer)

 

 

36

 

 

false --12-31 Q1 0001860657 0001860657 2022-01-01 2022-03-31 0001860657 2022-05-27 0001860657 2022-03-31 0001860657 2021-12-31 0001860657 us-gaap:SeriesAPreferredStockMember 2022-03-31 0001860657 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001860657 2021-01-01 2021-03-31 0001860657 us-gaap:SeriesAPreferredStockMember allr:ConvertiblePreferredStocksMember 2020-12-31 0001860657 us-gaap:CommonStockMember 2020-12-31 0001860657 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001860657 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2020-12-31 0001860657 us-gaap:RetainedEarningsMember 2020-12-31 0001860657 2020-12-31 0001860657 us-gaap:SeriesAPreferredStockMember allr:ConvertiblePreferredStocksMember 2021-01-01 2021-03-31 0001860657 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001860657 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001860657 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2021-01-01 2021-03-31 0001860657 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001860657 us-gaap:SeriesAPreferredStockMember allr:ConvertiblePreferredStocksMember 2021-03-31 0001860657 us-gaap:CommonStockMember 2021-03-31 0001860657 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001860657 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2021-03-31 0001860657 us-gaap:RetainedEarningsMember 2021-03-31 0001860657 2021-03-31 0001860657 us-gaap:SeriesAPreferredStockMember allr:ConvertiblePreferredStocksMember 2021-12-31 0001860657 us-gaap:CommonStockMember 2021-12-31 0001860657 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001860657 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2021-12-31 0001860657 us-gaap:RetainedEarningsMember 2021-12-31 0001860657 us-gaap:SeriesAPreferredStockMember allr:ConvertiblePreferredStocksMember 2022-01-01 2022-03-31 0001860657 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001860657 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001860657 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2022-01-01 2022-03-31 0001860657 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001860657 us-gaap:SeriesAPreferredStockMember allr:ConvertiblePreferredStocksMember 2022-03-31 0001860657 us-gaap:CommonStockMember 2022-03-31 0001860657 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001860657 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2022-03-31 0001860657 us-gaap:RetainedEarningsMember 2022-03-31 0001860657 2021-01-01 2021-12-31 0001860657 allr:LanternPharmaIncMember 2022-01-01 2022-03-31 0001860657 allr:IPRDAssetsMember 2022-03-31 0001860657 allr:AcquiredPatentsMember 2022-03-31 0001860657 allr:TotalIntangibleAssetsMember 2022-03-31 0001860657 allr:IPRDAssetsMember 2021-12-31 0001860657 allr:AcquiredPatentsMember 2021-12-31 0001860657 allr:TotalIntangibleAssetsMember 2021-12-31 0001860657 allr:StenoparibMember 2022-03-31 0001860657 allr:StenoparibMember 2021-12-31 0001860657 allr:DovitinibMember 2022-03-31 0001860657 allr:DovitinibMember 2021-12-31 0001860657 us-gaap:LoansPayableMember 2021-03-22 0001860657 us-gaap:LoansPayableMember 2021-03-01 2021-03-22 0001860657 us-gaap:LoansPayableMember 2021-03-31 0001860657 us-gaap:LoansPayableMember 2021-06-01 2021-06-23 0001860657 2022-04-01 2022-04-12 0001860657 us-gaap:ConvertibleNotesPayableMember 2022-03-31 0001860657 2019-12-31 0001860657 2019-01-01 2019-12-31 0001860657 2020-01-01 2020-12-31 0001860657 us-gaap:ConvertibleNotesPayableMember 2022-01-01 2022-03-31 0001860657 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-03-31 0001860657 2020-03-31 0001860657 2020-03-01 2020-03-31 0001860657 2021-05-20 2021-05-20 0001860657 allr:SeriesAConvertiblePreferredStockMember 2021-12-08 0001860657 allr:SeriesAConvertiblePreferredStockMember 2021-12-14 2021-12-14 0001860657 2021-12-01 2021-12-20 0001860657 us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-03-31 0001860657 2021-09-13 0001860657 2021-09-01 2021-09-13 0001860657 allr:SeriesAPreferredDerivativeLiabilityMember 2022-03-31 0001860657 allr:SeriesAPreferredDerivativeLiabilityMember 2021-12-31 0001860657 pf0:MinimumMember allr:SeriesAPreferredDerivativeLiabilityMember 2022-01-01 2022-03-31 0001860657 pf0:MaximumMember allr:SeriesAPreferredDerivativeLiabilityMember 2022-01-01 2022-03-31 0001860657 allr:SeriesAPreferredDerivativeLiabilityMember 2021-01-01 2021-12-31 0001860657 allr:MonteCarloSimulationModelMember 2021-12-31 0001860657 allr:SeriesAPreferredDerivativeLiabilityMember 2022-01-01 2022-03-31 0001860657 allr:MonteCarloSimulationModelMember 2021-01-01 2021-12-31 0001860657 allr:WarrantLiabilityMember 2021-12-21 2021-12-31 0001860657 allr:SeriesAPreferredDerivativeLiabilityMember 2021-12-21 2021-12-31 0001860657 allr:SeriesAConvertiblePreferredStockMezzanineEquityMember 2021-12-21 2021-12-31 0001860657 us-gaap:CommonStockMember 2021-12-21 2021-12-31 0001860657 us-gaap:AdditionalPaidInCapitalMember 2021-12-21 2021-12-31 0001860657 allr:FinanceCostsMember 2021-12-21 2021-12-31 0001860657 allr:ConsolidatedStatementOfOperationsComprehensiveLossMember 2021-12-21 2021-12-31 0001860657 allr:WarrantLiabilityMember 2021-12-31 0001860657 allr:SeriesAPreferredDerivativeLiabilityMember 2021-12-31 0001860657 allr:SeriesAConvertiblePreferredStockMezzanineEquityMember 2021-12-31 0001860657 allr:FinanceCostsMember 2021-12-31 0001860657 allr:ConsolidatedStatementOfOperationsComprehensiveLossMember 2021-12-31 0001860657 allr:WarrantLiabilityMember 2022-01-01 2022-03-31 0001860657 allr:SeriesAPreferredDerivativeLiabilityMember 2022-01-01 2022-03-31 0001860657 allr:SeriesAConvertiblePreferredStockMezzanineEquityMember 2022-01-01 2022-03-31 0001860657 us-gaap:AccruedLiabilitiesMember 2022-01-01 2022-03-31 0001860657 allr:SeriesAConvertiblePreferredStockMezzanineEquityMember 2020-12-21 2021-12-20 0001860657 us-gaap:AdditionalPaidInCapitalMember 2020-12-21 2021-12-20 0001860657 allr:WarrantLiabilityMember 2022-03-31 0001860657 allr:SeriesAPreferredDerivativeLiabilityMember 2022-03-31 0001860657 allr:ConsolidatedStatementOfOperationsComprehensiveLossFairValueAdjustmentToDerivativeLiabilityMember 2022-03-31 0001860657 allr:ConsolidatedStatementOfOperationsComprehensiveLossFairValueAdjustmentToDerivativeLiabilityMember 2022-01-01 2022-03-31 0001860657 2021-03-01 2021-03-31 0001860657 allr:iFundSeriesARedemptionFeatureMember 2021-12-31 0001860657 allr:SettlementWarrantsMember 2020-12-31 0001860657 allr:TO2WarrantsMember 2020-12-31 0001860657 allr:iFundSeriesARedemptionFeatureMember 2022-01-01 2022-03-31 0001860657 allr:SettlementWarrantsMember 2021-01-01 2021-03-31 0001860657 allr:TO2WarrantsMember 2021-01-01 2021-03-31 0001860657 allr:iFundSeriesARedemptionFeatureMember 2022-03-31 0001860657 allr:SettlementWarrantsMember 2021-03-31 0001860657 allr:TO2WarrantsMember 2021-03-31 0001860657 us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-12-31 0001860657 us-gaap:FairValueInputsLevel1Member 2022-03-31 0001860657 us-gaap:FairValueInputsLevel2Member 2022-03-31 0001860657 us-gaap:FairValueInputsLevel3Member 2022-03-31 0001860657 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001860657 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001860657 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001860657 2022-03-01 2022-03-28 0001860657 allr:SeriesAPreferredStockTriggeringEventMember 2022-01-01 2022-03-31 0001860657 us-gaap:SubsequentEventMember 2022-04-01 2022-04-29 0001860657 us-gaap:SeriesAPreferredStockMember us-gaap:SubsequentEventMember 2022-05-25 0001860657 us-gaap:SubsequentEventMember 2022-05-25 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:SEK iso4217:DKK